Investigations of the Lupus-Like Inhibitor By-Passing Activity of Platelets

Summary

Plasmas from ten patients with a lupus or lupus-like inhibitor were investigated. In each case the partial thromboplastin time with kaolin (PTTK) was prolonged and failed to correct on the addition of an equal volume of normal plasma. Activated control platelets corrected the inhibitory effect in the PTTK or thrombin generation time (TGT) in every instance. Activated autologous platelets were as effective as control platelets and may thus explain why bleeding is rarely associated with the lupus inhibitor. Experiments using platelets or plasma from patients congenitally deficient in a single clotting factor or normal washed platelets resuspended in deficient plasma indicated that the inhibitor bypassing activity is platelet and not plasma derived. Platelet fractionation studies suggested that this activity is localised at the platelet membrane.

Keywords

Lupus-like inhibitor - Platelet by-passing activity - Activated platelets

• References

• 1 Schleider MA, Nachman RL, Jaffe EA, Coleman M. A clinical study of the lupus anticoagulant. Blood 1976; 48: 499-509
• 2 Feinstein DI, Rapaport SI. Acquired inhibitors of blood coagulation. In: Progress in hemostasis and thrombosis. Spaet T. (eds) Grune & Stratton; New York: 1972. 1 75-95
• 3 Lechner K. A new type of coagulation inhibitor. Thromb Diathes Haemorrh 1969; 21: 482-499
• 4 Firkin BG, Booth P, Hendrix L, Howard MA. Demonstration of a platelet by-pass mechanism in the clotting system using an acquired anticoagulant. Am J Haematol 1978; 5: 81-92
• 5 Exner T, Rickard KA, Kronenberg H. A sensitive test demonstrating lupus anticoagulant and its behavioural patterns. Br J Haematol 1978; 40: 143-151
• 6 Thiagarajan P, Shapiro SS, De Marco L. Monoclonal immunoglobu-lin MX coagulation inhibitor with phospholipid specificity. Mechanism of a lupus anticoagulant J Clin Invest 1980; 66: 397-405
• 7 Denson KW E. Techniques. Human blood coagulation in haemostasis and thrombosis In: Biggs R. (eds) Oxford: Blackwell Scientific Publications; 1972. pp 602-675
• 8 Walsh PN. Albumin density gradient separation and washing of platelets and the study of platelet coagulant activities. Br J Haematol 1972; 22: 205-217
• 9 Firkin BG, Howard MA, Farmer SJ. Observations on the ultrastructure of platelets in Glanzmann’s disease. Br J Haematol 1974; 27: 527-531
• 10 Andes WA. IgM anticoagulation with acquired abnormalities in factor vIII. Thromb Res 1982; 27: 703-712
• 11 Canoso RT, Sise HS. Chlorpromazine-mduced lupus anticoagulant and associated immunologic abnormalities. Am J Haematol 1982; 13: 121-129
• 12 Clyne LP, Dainiak N, Hoffman R, Hardin J. In vitro correction of anticoagulant activity and specific clotting factor assays in SLE. Thromb Res 1980; 18: 643-655
• 13 Veltkamp JJ, Kerkhoven P, Loeliger EA. Circulating anticoagulant in disseminated lupus erythematosus. Haemostasis 1974; 2: 253-259
• 14 Coots MC, Miller MA, Glueck HI. The lupus inhibitor. A study of its heterogeneity Thromb Haemostas 1981; 46: 734-739
• 15 Exner T, Rickard KA, Kronenberg H. Studies on phospholipids in the action of a lupus coagulation inhibitor. Pathology 1975; 7: 319-328